vatalanib has been researched along with hoe 33342 in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (hoe 33342) | Trials (hoe 33342) | Recent Studies (post-2010) (hoe 33342) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 1,270 | 0 | 245 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allegrini, PR; Drevs, J; Esser, N; Fuxius, S; Hennig, J; Hugenschmidt, H; Konerding, MA; Marmé, D; Müller-Driver, R; Unger, C; Wittig, C; Wood, J | 1 |
1 other study(ies) available for vatalanib and hoe 33342
| Article | Year |
|---|---|
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Blood Vessels; Capillary Permeability; Carcinoma, Renal Cell; Enzyme Inhibitors; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorescent Dyes; Heterocyclic Compounds; Kidney Neoplasms; Magnetic Resonance Angiography; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow | 2002 |